BARcure

Company Overview

Snapshot

Founded in June 2017, BARcure operated with 1–10 employees, focusing on developing novel immunotherapies. The company ceased operations in April 2019.

Business overview

BARcure is a biopharmaceutical company developing a therapeutic platform for various B-cell neoplasms, primarily non-Hodgkin's lymphoma (NHL). The company's core technology involves novel immunotherapies designed to specifically target malignant B cells while sparing normal B cells. BARcure focuses on developing BAR-based products for treating diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), leveraging research from Saarland University in Germany. It operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drug Delivery, targeting the pharmaceutical market.

Company Intelligence Q&A

What is BARcure's primary focus?

BARcure's primary focus is on developing a therapeutic platform for B-cell malignancies, specifically non-Hodgkin's lymphoma (NHL), by targeting malignant B cells with novel immunotherapies.

When was BARcure founded?

BARcure was founded in June 2017.

What is the status of BARcure?

BARcure is currently non-active, having ceased operations in April 2019.

What type of products was BARcure developing?

BARcure was developing BAR-based products for the treatment of DLBCL and MCL, utilizing novel immunotherapies.

Which research institution did BARcure leverage for its technology?

BARcure leveraged research work done by Prof. Michael Pfreundschuh from Saarland University in Germany.